Iterum Therapeutics (ITRM) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ITRM Iterum Therapeutics

Watchlist

1.0300
+0.0100+0.98%

Close Oct 16 16:00 ET

1.0477
+0.0177+1.72%

Post 20:01 ET

23.39MMarket Cap-517P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Iterum Therapeutics to Present Data at IDWeek 2024
GlobeNewswireOct 10 08:30 ET
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
GlobeNewswireOct 9 17:00 ET
Express News | Iterum Therapeutics: Got Delisting Determination Letter Advising That Nasdaq Determined Co Did Not Meet Terms of Extension for Compliance
ReutersOct 4 17:22 ET
Express News | Iterum Therapeutics PLC: Seeks Share Issue Approval at Egm
ReutersSep 30 16:37 ET
Express News | Iterum Therapeutics PLC: Egm Adjourned Until Oct 8, 2024- Filing
ReutersSep 30 16:37 ET
Iterum Stock Falls 9% in Wake of FDA AdComm Meeting on UTI Drug
Seeking AlphaSep 10 10:48 ET

Comments

Meltyy

Oct 15 01:52

1 PDUFA & 1 AdCom left in October 🗓️

See FDA PDUFA update 👇
$Iterum Therapeutics (ITRM.US)$ : 🤔
⇨ Oral Sulopenem
‣ Uncomplicated Urinary Tract Infections
‣ PDUFA: 10/25/24
$Lexicon Pharmaceuticals (LXRX.US)$ : [Adcom] 🤔
⇨ ZYNQUISTA (sotagliflozin)
‣ Type 1 Diabetes
‣ Adcom: 10/31/24
📣 Last Week’s PDUFA Decisions:
$ZLDPF: CRL 10/8 ❌
⚠️ due to timing of a 3rd-party mfg. facility reinspection
⇨ Dasiglucagon
‣ Congenital Hyperinsulinism
‣ PDUFA: 10/08/24 (NDA)
$RRBHY: Approved 10/11 ✅
⇨ Itovebi™ (inavolis...

SkinnyChick

Sep 10 09:13

$Iterum Therapeutics (ITRM.US)$ the dip to buy

103622690 DK

Sep 10 07:23

$Iterum Therapeutics (ITRM.US)$ Iterum Therapeutics PLC - Potential to Be First Oral Penem Approved in U.S.

Trytosaveabit

Sep 10 06:42

I would say!

$Iterum Therapeutics (ITRM.US)$ Average .10 spread so far on a 1.00 ticker! Needs a bit more liquidity! Hehehe

Trytosaveabit

Sep 10 06:16

A bit more

$Iterum Therapeutics (ITRM.US)$ Iterum announced that a meeting of the FDA Antimicrobial Drugs Advisory Committee (AMDAC) took place on September 9, 2024 at which Iterum's new drug application (NDA) for sulopenem etzadroxil/probenecid (oral sulopenem) for the treatment of uncomplicated urinary tract infections (uUTI) in adult women was discussed.
"We are encouraged by the AMDAC's discussion which acknowledged oral sulopenem as an important treatment option for certain patients with uUTI...

Analyst Rating

No Data

Price Target

No Data

Heat List

Overall

No Data

ITRM Iterum Therapeutics

Trade Overview

Capital Trend

News

Comments

Analysis

Analyst Rating

Price Target